ストックスクリーナーアプリを入手
1.71
8.92%
0.14
アフターアワーズ：
1.70
-0.01
-0.58%
Lexicon Pharmaceuticals Inc (LXRX) 最新ニュース
LIVE: Lexicon Pharmaceuticals Rings the Closing Bell - Nasdaq
How A Reset Price Target Is Reframing The Story For Lexicon Pharmaceuticals (LXRX) - Yahoo Finance
Risk Report: Can Lexicon Pharmaceuticals Inc reach all time highs this year - baoquankhu1.vn
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Given Consensus Rating of "Hold" by Brokerages - MarketBeat
Lexicon Pharma spikes after FDA feedback on pain drug - MSN
Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) Shows High-Growth Momentum with Strong Technical and Fundamental Trends - Chartmill
Lexicon Pharmaceuticals to Ring the Nasdaq Closing Bell on January 27, 2026 to Celebrate 30th Anniversary - Yahoo Finance
Downgrade Watch: How does Lexicon Pharmaceuticals Inc compare to its peersJuly 2025 Pullbacks & Safe Entry Trade Reports - baoquankhu1.vn
Lexicon rebounds on FDA nod for phase III non-opioid pain drug trial - BioWorld MedTech
Lexicon Pharmaceuticals: 'Hold' As FDA Feedback Allows Pilavapadin For DPNP To Go Forward - Seeking Alpha
Lexicon Pharmaceuticals (NASDAQ:LXRX) Reaches New 52-Week HighHere's Why - MarketBeat
Lexicon Pharmaceuticals, Inc.'s (NASDAQ:LXRX) Shares Climb 28% But Its Business Is Yet to Catch Up - simplywall.st
Lexicon Pharmaceuticals (NASDAQ:LXRX) Sees Strong Trading VolumeWhat's Next? - MarketBeat
Lexicon Pharmaceuticals Boosts Outlook with Strategic Moves - StocksToTrade
Lexicon Pharmaceuticals (LXRX) Soars on Positive FDA Meeting Out - GuruFocus
Lexicon Pharma rises on FDA views on pain drug (LXRX:NASDAQ) - Seeking Alpha
Lexicon (LXRX) Receives FDA Green Light for Phase 3 Trials on Pi - GuruFocus
Lexicon Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA For Pilavapadin in the Treatment of Diabetic Peripheral Neuropathic Pain - manilatimes.net
Lexicon Pharmaceuticals Advances Pilavapadin to Phase 3 Development for Diabetic Peripheral Neuropathic Pain After FDA Meeting - Quiver Quantitative
Lexicon Pharmaceuticals announces successful end-of-phase 2 meeting with FDA for pilavapadin in the treatment of diabetic peripheral neuropathic pain - marketscreener.com
Lexicon Pharmaceuticals Announces Successful End-Of-Phase 2 Meeting With FDA For Pilavapadin In The Treatment Of Diabetic Peripheral Neuropathic Pain - TradingView
Diabetic Neuropathy Clinical Trial Pipeline Gains Momentum: 18+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - The Manila Times
Viatris Expands Innovative Portfolio in Cardiovascular Diseases with the Company's First Launch of Inpefa® (Sotagliflozin) for the Treatment of Heart Failure - Sahm
Is Lexicon Pharmaceuticals Inc. stock a bargain at current levelsQuarterly Profit Report & Free Community Consensus Stock Picks - bollywoodhelpline.com
Lexicon Pharmaceuticals (NASDAQ:LXRX) delivers shareholders notable 99% return over 1 year, surging 17% in the last week alone - simplywall.st
Lexicon Pharmaceuticals (NASDAQ:LXRX) Trading 8.2% HigherTime to Buy? - MarketBeat
Lexicon flags $10 mln Novo Nordisk milestone and 2026 NDA plans - MSN
Aug PreEarnings: Will Lexicon Pharmaceuticals Inc. stock deliver long term returnsQuarterly Market Summary & Expert Approved Momentum Trade Ideas - Bộ Nội Vụ
Published on: 2026-01-13 21:48:56 - Bộ Nội Vụ
Lexicon Pharmaceuticals Publishes Relief is Possible, Ensuring Access to Effective Treatments for Chronic Pain - marketscreener.com
Lexicon Pharmaceuticals provides a business and pipeline update at the 44th annual J.P. Morgan healthcare conference - marketscreener.com
Lexicon Pharmaceuticals Provides a Business and Pipeline Update at the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
Experimental heart, diabetes and pain drugs move ahead at Lexicon - Stock Titan
Published on: 2026-01-10 20:09:17 - ulpravda.ru
Lexicon Pharmaceuticals Releases White Paper on Addressing Chronic Pain with Non-Opioid Treatments Following Stakeholder Roundtable - Quiver Quantitative
Rockford Register Star: Local News, Politics & Sports in Rockford, IL - FinancialContent
Will Lexicon Pharmaceuticals Inc. stock maintain growth storyAnalyst Downgrade & Fast Gain Stock Tips - Улправда
Making Medical Innovation Matter To Patients With Simplified Trial Design - Clinical Leader
Is Lexicon Pharmaceuticals Inc. stock cheap at current valuationTrade Performance Summary & Growth-Oriented Investment Plans - Улправда
Market Rankings: Can Lexicon Pharmaceuticals Inc. stock continue upward trendMarket Performance Recap & Scalable Portfolio Growth Ideas - ulpravda.ru
Is Lexicon Pharmaceuticals Inc. stock resilient to inflationJuly 2025 PostEarnings & Real-Time Buy Signal Notifications - Улправда
Lexicon Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
Lexicon Pharmaceuticals Inc Stock Analysis and ForecastInstitutional Buying Trends & Calculate Profit Targets With AI Accuracy - earlytimes.in
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat
Aug Update: Will Lexicon Pharmaceuticals Inc stock outperform Dow Jones index2025 Big Picture & Low Drawdown Trading Strategies - moha.gov.vn
Lexicon Pharmaceuticals (NASDAQ:LXRX) Is Using Debt Safely - 富途牛牛
Profit Recap: Can Lexicon Pharmaceuticals Inc stock continue upward trendRisk Management & Free Daily Entry Point Trade Alerts - moha.gov.vn
Lexicon Pharmaceuticals (NASDAQ:LXRX) Shares Cross Above Two Hundred Day Moving AverageShould You Sell? - MarketBeat
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) stock most popular amongst private equity firms who own 48%, while individual investors hold 27% - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (BMRN), Lexicon Pharmaceuticals (LXRX) and Pfizer (PFE) - The Globe and Mail
Lexicon Pharmaceuticals accelerates partnerships with patients on innovative therapies - Traders Union
2.09%
0.48%
大文字化:
|
ボリューム (24 時間):